China NT Pharma Group Company Limited (1011.HK)
HKD 0.27
(1.89%)
HKD 0.27
(1.89%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 50.47 Million | 36.21 Million | -134.77 Million | 26.2 Million | 47.76 Million | -124.2 Million |
| Net Income | -126.6 Million | -54.29 Million | -148.75 Million | -368.93 Million | -583.47 Million | -923.9 Million |
| Depreciation & Amortization | 5.88 Million | 21.07 Million | 42.24 Million | 24.39 Million | 31.13 Million | 35.64 Million |
| Deferred income taxes | - | - | -12.31 Million | 140.24 Million | 457.42 Million | 610.64 Million |
| Stock-based compensation | 37.7 Million | 604 Thousand | 84 Thousand | 101 Thousand | 7.46 Million | 8.26 Million |
| Change in working capital | 81.51 Million | -12.18 Million | -92.17 Million | 135.42 Million | 2.87 Million | -238.71 Million |
| Other non-cash items | 48.95 Million | 81.02 Million | 76.13 Million | 94.96 Million | 132.34 Million | 383.86 Million |
| Investing Cash Flow | -22.14 Million | 4.53 Million | 257.81 Million | 595.6 Million | -206.87 Million | -143.24 Million |
| Investments in PPE | -12.89 Million | -4.49 Million | -646 Thousand | -23.84 Million | -87.2 Million | -240.88 Million |
| Acquisitions | -197 Thousand | 9 Million | 200.14 Million | 557.34 Million | -74.77 Million | 68 Million |
| Investment purchases | - | - | - | -44.79 Million | - | - |
| Sales/Maturities of investments | - | - | - | 44.79 Million | - | - |
| Other Investing Activities | -9.22 Million | 24 Thousand | 58.31 Million | 62.1 Million | -44.9 Million | 29.64 Million |
| Financing Cash Flow | -28.97 Million | -46.67 Million | -124.79 Million | -624.24 Million | 101.37 Million | 219.01 Million |
| Debt repayment | -18.17 Million | -80.47 Million | -162.24 Million | -1.73 Billion | -1.06 Billion | -1.19 Billion |
| Dividends payments | - | - | - | - | - | -56.7 Million |
| Common Stock Repurchased | - | - | - | - | -1.04 Million | -8.78 Million |
| Common Stock Issuance | 9.39 Million | 2.02 Million | - | - | - | 1.49 Billion |
| Other Financing Activities | -9.85 Million | 31.78 Million | 37.45 Million | 1.11 Billion | 1.17 Billion | -8.78 Million |
| Accounts receivables | 67.32 Million | -32.1 Million | 7.94 Million | 26.53 Million | 2.74 Million | -126.54 Million |
| Accounts payables | - | 32.1 Million | -7.94 Million | -26.53 Million | -2.74 Million | 126.54 Million |
| Inventory | -2.52 Million | 19.88 Million | -5.18 Million | 6.78 Million | 8.14 Million | 4.23 Million |
| Other working capital | 16.71 Million | -32.07 Million | -86.98 Million | 128.64 Million | -5.26 Million | -242.94 Million |
| Cash at beginning of period | 1.91 Million | 4.36 Million | 7.83 Million | 28.19 Million | 87.79 Million | 146.86 Million |
| Cash at end of period | 1.52 Million | 1.91 Million | 9.44 Million | 7.83 Million | 28.19 Million | 87.79 Million |
| Capital Expenditure | -12.89 Million | -4.49 Million | -646 Thousand | -23.84 Million | -87.2 Million | -240.88 Million |
| Effect of forex changes on cash | 240 Thousand | 3.48 Million | 3.36 Million | -17.92 Million | -1.85 Million | -10.64 Million |
| Net cash flow / Change in cash | -396 Thousand | -2.44 Million | 1.6 Million | -20.36 Million | -59.59 Million | -59.07 Million |
| Free Cash Flow | 37.58 Million | 31.71 Million | -135.42 Million | 2.36 Million | -39.43 Million | -365.08 Million |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 661 Thousand | -126.6 Million | - | -5.61 Million | -54.29 Million | -38.16 Million |
| Depreciation & Amortization | 511 Thousand | 5.88 Million | - | 10.53 Million | 21.07 Million | 9.37 Million |
| Deferred income taxes | - | - | - | - | - | 11.61 Million |
| Stock-based compensation | - | 37.7 Million | - | - | 604 Thousand | 604 Thousand |
| Change in working capital | - | 81.51 Million | - | - | -12.18 Million | -11.15 Million |
| Other non-cash items | -6.91 Million | 48.95 Million | - | 6.87 Million | 81.02 Million | 50.69 Million |
| Investing Cash Flow | -129 Thousand | -22.14 Million | - | -1.92 Million | 4.53 Million | 6.61 Million |
| Investments in PPE | -131 Thousand | -12.89 Million | - | -1.93 Million | -4.49 Million | -2.4 Million |
| Acquisitions | - | -197 Thousand | - | - | 9 Million | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 2000.00 | -9.22 Million | - | 17 Thousand | 24 Thousand | 9.01 Million |
| Financing Cash Flow | 4.27 Million | -28.97 Million | - | -8.39 Million | -46.67 Million | -20.08 Million |
| Debt repayment | - | -18.17 Million | - | - | -80.47 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 9.39 Million | - | - | 2.02 Million | - |
| Other Financing Activities | 4.27 Million | -9.85 Million | - | -8.39 Million | 31.78 Million | -20.08 Million |
| Accounts receivables | - | 67.32 Million | - | - | -32.1 Million | -32.1 Million |
| Accounts payables | - | - | - | - | 32.1 Million | - |
| Inventory | - | -2.52 Million | - | - | 19.88 Million | 19.88 Million |
| Other working capital | - | - | - | - | -32.07 Million | 1.06 Million |
| Cash at beginning of period | 1.52 Million | 1.91 Million | 12.05 Million | 5.93 Million | 4.36 Million | 16.94 Million |
| Cash at end of period | 5.79 Million | 1.52 Million | 12.05 Million | 12.05 Million | 1.91 Million | 6.99 Million |
| Capital Expenditure | -131 Thousand | -12.89 Million | - | -1.93 Million | -4.49 Million | -2.4 Million |
| Effect of forex changes on cash | 5.86 Million | 240 Thousand | - | 4.64 Million | 3.48 Million | -7.81 Million |
| Net cash flow / Change in cash | 4.27 Million | -396 Thousand | - | 6.12 Million | -2.44 Million | -9.95 Million |
| Free Cash Flow | -5.87 Million | 37.58 Million | - | 9.86 Million | 31.71 Million | 8.93 Million |
KFAST-B
600562
ABSO
SDURF
PAY
8795